Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
about
Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁Contribution of air pollution to COPD and small airway dysfunctionCOPD and its comorbidities: Impact, measurement and mechanismsComorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and ManagementChronic obstructive pulmonary diseaseDifferential expression of C-reactive protein and serum amyloid A in different cell types in the lung tissue of chronic obstructive pulmonary disease patientsAssociation Between the Inflammatory Biomarkers and Left Ventricular Systolic Dysfunction in Patients with Exacerbations of Chronic Obstructive Pulmonary DiseaseMultiple biomarkers predict disease severity, progression and mortality in COPD.Interleukin-6 and interleukin-8 blood levels' poor association with the severity and clinical profile of ex-smokers with COPD.Epidemiology and clinical impact of major comorbidities in patients with COPD.The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes.Chronic obstructive pulmonary disease: respiratory review of 2014.Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities.Comorbidities and burden of COPD: a population based case-control study.Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.Aging-related systemic manifestations in COPD patients and cigarette smokers.Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohortAnalysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer.Biomarkers of early chronic obstructive pulmonary disease (COPD) in smokers and former smokers. Protocol of a longitudinal study.Morbidity and Mortality in 7,684 Women According to Personal Hair Dye Use: The Copenhagen City Heart Study followed for 37 YearsInteractions among Lung Cancer Cells, Fibroblasts, and Macrophages in 3D Co-Cultures and the Impact on MMP-1 and VEGF Expression.Gene Expression Profiling of Pulmonary Artery in a Rabbit Model of Pulmonary Thromboembolism.Survival in COPD: impact of lung dysfunction and comorbidities.Prevalence of airflow obstruction in patients with stable systolic heart failure.Mental health, serum biomarkers and survival in severe COPD: a pilot study.Systemic inflammation and lung function: A longitudinal analysisAssociation of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease.Efficiency and outcome of non-invasive versus invasive positive pressure ventilation therapy in respiratory failure due to chronic obstructive pulmonary diseaseAssociation of biomarkers of inflammation and cell adhesion with lung function in the elderly: a population-based study.Relationship between plasma fibrinogen levels and pulmonary function in the japanese population: the Takahata study.Mechanism of intestinal mucosal barrier dysfunction in a rat model of chronic obstructive pulmonary disease: An observational study.The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease.Effect of thyroid function on COPD exacerbation frequency: a preliminary study.Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification.A simple clinical measure of quadriceps muscle strength identifies responders to pulmonary rehabilitation.Lung density on high resolution computer tomography (HRCT) reflects degree of inflammation in smokers.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
P2860
Q26764897-0E81B341-7838-4196-A008-EEA71FAB2614Q26786159-F8C7DE5C-EBFD-42AB-B52F-FDF0BF145194Q26786812-52332E8E-25B0-41AE-A308-FD7E723DD8DCQ26799659-11172460-A20C-4831-BE5A-724D628B9751Q27027955-F73D1F39-263B-4685-8FB9-62C2A482C049Q33732176-FB88EEE0-14E2-4CE9-801B-84B997DADF96Q33745263-4A7A04BE-D1A2-4102-83D5-99C3D72990FDQ33796180-887D7DFB-A837-4A8D-8017-658591C1661EQ34005625-B7CBCE4D-F0F0-45B5-B984-FD9AE2A4AB31Q34134841-947C0539-1A00-4BB0-BB35-D1C1607B75DFQ34346490-1E2E6D6E-CCC2-4036-ACB2-FED682C26C1EQ34440060-5EE971BC-FBDA-485B-9FD2-29C4697170CBQ34636461-487A1E85-366D-48ED-99F2-2AF136021D2DQ34656726-8940A467-7611-48C5-959D-4EFD5500A534Q34730130-4A7D6A3B-951D-486E-ACDB-476EBA843303Q35087187-086314A3-FF18-44BB-A72B-C0CA29E6A137Q35100841-9E2E70A6-B575-4D4F-B5E0-0B199C192732Q35192574-BB8F98A9-A7C7-45D4-A6B1-66E07672ADE8Q35493901-90AD4E59-0B99-4076-ACA3-329CEF5315F7Q35835036-8E734511-BC98-4830-9F45-44CD8615980AQ35897669-6FEDA0A9-5D45-4FFF-85B5-8D070FE08D71Q35948272-21CB5F4E-EA0C-45A5-828F-1180E6E941D0Q35960724-79DD5B22-A2A9-4B79-95B0-C56E55AC719FQ36032456-4BE96D9C-194B-4B20-AE38-17E8CB7EC115Q36178531-535CF85D-5908-442F-9B73-FF0B31958F2FQ36193333-1351893F-DEF2-4DA2-B198-CD59963F96DDQ36243275-6AD7FB7D-398E-4BAB-A199-A23EA34A7740Q36476007-434CF162-F33C-4C52-B5E7-8CBFD623FFFBQ36585291-50847F18-3240-40D4-B345-16F2F6E44EC6Q36967440-B95632CE-E400-44DE-A93B-C06132B50E48Q37020656-D9C3811B-E938-4D0C-AD3A-49FB8F2DB63EQ37113883-207D9E4B-C4EA-4D6A-B6C9-EC4852E698C6Q37176968-181010F7-D389-48E0-88A3-B1144978BC8CQ37204135-15A18FBD-B2BE-4C80-BC15-A2203FEF87A1Q37307527-30A4F05E-5007-4801-88A2-379BD91FDB80Q37354310-9C5CA09B-1665-4001-B5EC-A865671684D8Q37563167-15610E72-4467-4395-BD1E-9B1D716D1EDFQ37593790-C9DF016C-26EC-4B65-9ED0-91A1443BB8B7Q37621586-C78FCE4C-DDA5-47C6-8FC8-9FAAE115DADFQ37734257-DBF96482-BE5B-4266-94E1-DF71411ACC15
P2860
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@en
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@nl
type
label
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@en
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@nl
prefLabel
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@en
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@nl
P2860
P50
P1476
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
@en
P2093
Mette Thomsen
Peter Lange
P2860
P304
P356
10.1164/RCCM.201206-1113OC
P407
P577
2012-09-13T00:00:00Z